Swissmedic has approved subcutaneous administration of Pamorelin® LA 3.75 mg and 11.25 mg for prostate cancer treatment
Lausanne, Switzerland – September 4th, 2025 – Debiopharm (www.debiopharm.com), an independently-owned Swiss biopharmaceutical company committed to developing tomorrow’s standard-of-care treatments to cure cancer and infectious diseases, announced that Swissmedic approved, as of May 16, 2025, the subcutaneous administration of Pamorelin® LA 3.75 mg and Pamorelin® LA 11.25 mg (triptorelin embonate) for the treatment of prostate cancer. This new administration route complements the doses already approved for intramuscular injection (3.75mg, 11.25mg and 22.5mg). Subcutaneous administration of Pamorelin® has demonstrated equivalent efficacy and safety compared to the well-established intramuscular route¹,².
A comfortable and flexible alternative for patients and healthcare professionals, in general, the subcutaneous injection is less painful, better tolerated by patients on anticoagulants, reduces the risk of hematoma, and is ideal for individuals with low muscle mass or those who are averse to intramuscular injections.
For healthcare professionals, it offers the same efficacy and safety as intramuscular administration, with no changes to dosing schedules, storage conditions, or preparation requirements. This allows seamless integration into existing protocols. Having both options enables tailoring treatment to each patient’s profile and preferences, supporting a more personalized approach.
Prostate cancer is the most common cancer among men in Switzerland, with an average of 7,827 new cases and 1,356 deaths annually³,⁴. The medical care of these patients highlights the critical need for better-tolerated and more comfortable treatment options to improve the quality of life of patients throughout their care journey.
“ This is great news for men facing prostate cancer in Switzerland. This approval marks a meaningful step towards more personalized and practical care for patients, giving healthcare professionals the flexibility to adapt administration to individual patient needs and clinical settings”, said Catalin Tamas, Head of Medical Affairs at Debiopharm. “Continuous development of new, long-acting-release formulations of triptorelin, reflects our commitment to advancing prostate cancer care, addressing the evolving clinical needs in the management of this disease.”
Already approved in several other countries, this new administration option enhances flexibility by allowing healthcare providers to tailor treatment based on clinical needs, institutional practices, and individual patient preferences.
Updated product information for Pamorelin® LA 3.75 mg and 11.25 mg is available at https://www.swissmedicinfo.ch
About Pamorelin® (Triptorelin)
Pamorelin® is a GnRH agonist used in the treatment of prostate cancer. Debiopharm has developed three long-acting formulations (1-, 3-, and 6-month) of triptorelin pamoate and is currently developing a 12-month formulation. Triptorelin is manufactured in Switzerland at Debiopharm’s production site in Martigny and is marketed in Switzerland by Debiopharm and in over 80 countries through selected big pharmaceutical partners. It is a market leader and reference treatment in many regions worldwide.
Debiopharm’s Commitment to Patients
Debiopharm aims to develop innovative treatments that address high unmet medical needs, primarily in oncology and bacterial infections. Bridging the gap between breakthrough discoveries and real-world patient access, the company identifies high-potential molecules and technologies for licensing, clinically demonstrates their safety and efficacy, and partners with major pharmaceutical companies to ensure global patient access.
For more information, visit https://www.debiopharm.com
Follow us on LinkedIn: https://www.linkedin.com/company/debiopharminternational/
References :
3 https://krebs-monitoring.bfs.admin.ch/fr/comparaison/nouveaux-cas/
4 https://krebs-monitoring.bfs.admin.ch/fr/comparaison/deces/